目的:评价多西他赛、奥沙利铂、氟尿嘧啶联合化疗方案(DOF方案)对进展期胃癌的疗效和不良反应。方法:65例进展期胃癌随机入组DOF方案组(n=33)和奥沙利铂联合氟尿嘧啶(FOLFOX4)方案组(n=32),观察两组的临床疗效和不良反应。结果:DOF方案组的有效率(RR)为51.5%,中位无进展时间(TTP)为8.6个月,1年生存率为57.3%;FOLFOX4方案组的RR为46.9%,TTP为5.8个月,1年生存率为41.2%。统计学分析提示,两组客观有效率相似(P>0.05);DOF方案组的TTP和1年生存率优于FOLFOX4方案组,差异有统计学意义(P<0.05);DOF方案组的中性粒细胞减少、血小板减少和脱发的发生率高于FOLFOX4方案组,差异有统计学意义(P<0.05)。结论:DOF方案治疗进展期胃癌疗效较好,不良反应可耐受,值得临床上推广应用。 OBJECTIVE: To evaluate the efficacy and side effects of docetaxel, oxaliplatin and fluorouracil in combination with chemotherapy regimen (DOF) on advanced gastric cancer. Methods: A total of 65 patients with advanced gastric cancer were enrolled in the DOF regimen (n = 33) and the oxaliplatin combined with fluorouracil regimen (n = 32). The clinical efficacy and adverse reactions of the two groups were observed. Results: The effective rate (RR) of DOF group was 51.5%, the median progression-free time (TTP) was 8.6 months and the 1-year survival rate was 57.3%. The RR of FOLFOX4 group was 46.9% and the TTP was 5.8 months Year survival rate was 41.2%. The statistical analysis showed that the two groups had similar objective effective rates (P> 0.05). The TTP and 1-year survival rates of DOF group were better than those of FOLFOX4 group (P <0.05) The incidence of neutropenia, thrombocytopenia and hair loss was higher than that of FOLFOX4 regimen (P <0.05). Conclusion: The DOF regimen is effective in treating advanced gastric cancer and its adverse reactions are tolerable. It is worth to be popularized clinically.